News By: Emily Norris

Clinical research sites are at a transformative juncture, facing heightened demands to deliver trials with greater speed, efficiency, and quality than ever before. As the industry embraces rapid innovation, digital transformation, and more complex protocols, pressures are intensifying at the site level, where budget constraints, funding cuts, and operational demands continue to grow. Today’s research sites must navigate a multifaceted landscape, contending with fragmented communications, persistent technology changes, and the need to recruit and retain skilled talent, among other obstacles.   

Clinical research participants should reflect the disease population in question. This statement is a no-brainer; however, drug and device developers and clinical trials teams have failed countless times at accomplishing this task. 

The clinical research enterprise shapes the medicine of today and tomorrow, serving all people through meaningful collaboration. However, we cannot achieve impactful outcomes without buy-in from all of its stakeholders, whether as caregivers, personal advocates, healthcare professionals, clinical research professionals, industry partners, or participants. 

The six-day, 355-mile cycling journey from Pittsburgh, Pa., to Washington, D.C., raises funds for the ACRP Access for Students to Clinical Research Training (ASCRT) Scholarship Program, ACRP Certification Scholarship, and educational grants for the ACRP Annual Conference.

The global clinical research community watched closely for the release of ICH E6(R3) Good Clinical Practice (GCP), the long-awaited update to the foundational guideline from the International Council on Harmonization (ICH). On September 9, 2025, the U.S. Food and Drug Administration (FDA) posted the final version on its website and published it in the Federal Register. This signals that the guideline is officially available in the United States and provides a clear reference point for industry and regulators alike.